STOCK MARKET BSE NSE

Merck’s Covid pill -- Molnupriravir -- close to regulator nod

The drug Molnupriravir, a broad spectrum antiviral, has shown promise in international trials in halting the progression of Covid in its early stages.

Published: 14th November 2021 06:42 AM  |   Last Updated: 14th November 2021 06:42 AM   |  A+A-

pills, tablets, medicines

For representational purposes

Express News Service

NEW DELHI: The oral Covid pill developed by US drug major Merck and Ridgeback Biotherapeutics could be launched in coming weeks in the India market, with the full treatment course estimated to cost Rs 500-Rs 1,000.

The drug Molnupriravir, a broad spectrum antiviral, has shown promise in international trials in halting the progression of Covid in its early stages. Last week, the UK became the first country in the world to approve the drug, recommending its use right after a positive coronavirus test and within five days of the onset of symptoms.

Sources in India’s Central Drugs Standard Control Organisation told this newspaper that the regulator could give its verdict on the restricted emergency use of the medicine as early as this week as it is in the final stage of reviewing data from about 700 patients in India. “This could pave the way for the launch of the oral Covid-19 pill in the coming weeks,” said a senior official.

Officials in the department of science and technology said they expect the drug to be priced in the range of Rs 25-50 per tablet. A patient would need to take 15-20 tablets over a five-day treatment course. “We are hoping that for every patient a course of this drug may cost only about Rs 500-1000 which will be very affordable,” said a high ranking official. Sun Pharma, one of the companies licensed to make the drug in India, on Thursday said that the firm will launch it under the name Molxvir at an “economical price.” 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp